Abstract | BACKGROUND: PATIENTS AND METHODS: Forty-eight patients aged 18-75 years with Eastern Cooperative Oncology Group performance status 0-2, confirmed adenocarcinoma or activating epidermal growth factor receptor (EGFR) mutation-positive NSCLC, and asymptomatic BM without extracranial progressive disease after first-line platinum-doublet chemotherapy were recruited. Treatment comprised erlotinib 150 mg/day. The primary end point was progression-free survival (PFS) determined by RECIST. RESULTS: The median PFS was 10.1 months [95% confidence interval (CI) 7.1-12.3] for intracranial progression and 9.7 months (95% CI 2.5-17.8) for intracranial and systemic progression. Patients with EGFR mutation-positive disease had significantly longer median PFS versus EGFR wild-type disease [15.2 months (95% CI 8.3-22.2) versus 4.4 months (95% CI 0.0-11.6); P = 0.02]. The median overall survival was 18.9 months (95% CI 14.4-23.4); 6-month and 1-year survival rates were 85% and 73%, respectively. Overall response rate was 58.3%. Most common adverse events were rash (77.1%), paronychia (20.8%), hyperbilirubinemia (16.7%), and diarrhea (14.6%); these were predominantly of grade 1/2. CONCLUSIONS: Single-agent erlotinib was active and well tolerated in NSCLC patients with BM. Further studies are warranted.
|
Authors | Y-L Wu, C Zhou, Y Cheng, S Lu, G-Y Chen, C Huang, Y-S Huang, H-H Yan, S Ren, Y Liu, J-J Yang |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 24
Issue 4
Pg. 993-9
(Apr 2013)
ISSN: 1569-8041 [Electronic] England |
PMID | 23129122
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Quinazolines
- Erlotinib Hydrochloride
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Adolescent
- Adult
- Aged
- Brain Neoplasms
(drug therapy, genetics, pathology, secondary)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions
(chemically induced, pathology)
- ErbB Receptors
(genetics)
- Erlotinib Hydrochloride
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Staging
- Quinazolines
(administration & dosage, adverse effects)
|